Guizhou Yibai Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Guizhou Yibai Pharmaceutical Co Ltd cash flow-to-debt ratio. Guizhou Yibai Pharmaceutical Co Ltd (600594) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥33.28 Million could theoretically repay 0% of its total liabilities (CN¥1.32 Billion) in one year. Check earnings quality score of Guizhou Yibai Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Guizhou Yibai Pharmaceutical Co Ltd (2002–2025)
Cash flow-to-debt ratio of Guizhou Yibai Pharmaceutical Co Ltd from 2002 to 2025. Historical debt coverage capacity for Guizhou Yibai Pharmaceutical Co Ltd across 24 annual periods. Check cash flow reinvestment rate of Guizhou Yibai Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Guizhou Yibai Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2002–2025)
Guizhou Yibai Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Guizhou Yibai Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 600594 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | CN¥256.71 Million | CN¥1.17 Billion | ▲ +276.8% |
| 2024 | 0.06x | CN¥86.87 Million | CN¥1.49 Billion | ▼ -75.7% |
| 2023 | 0.24x | CN¥377.61 Million | CN¥1.58 Billion | ▲ +16.1% |
| 2022 | 0.21x | CN¥345.30 Million | CN¥1.68 Billion | ▼ -66.8% |
| 2021 | 0.62x | CN¥934.21 Million | CN¥1.51 Billion | ▲ +198.4% |
| 2020 | 0.21x | CN¥366.66 Million | CN¥1.76 Billion | ▲ +8.6% |
| 2019 | 0.19x | CN¥362.71 Million | CN¥1.89 Billion | ▲ +129.1% |
| 2018 | 0.08x | CN¥214.30 Million | CN¥2.56 Billion | ▼ -68.7% |
| 2017 | 0.27x | CN¥681.78 Million | CN¥2.55 Billion | ▲ +68.1% |
| 2016 | 0.16x | CN¥380.62 Million | CN¥2.40 Billion | ▼ -43.6% |
| 2015 | 0.28x | CN¥573.68 Million | CN¥2.04 Billion | ▲ +7.7% |
| 2014 | 0.26x | CN¥541.58 Million | CN¥2.07 Billion | ▼ -42.5% |
| 2013 | 0.46x | CN¥577.24 Million | CN¥1.27 Billion | ▲ +15.6% |
| 2012 | 0.39x | CN¥288.01 Million | CN¥731.33 Million | ▼ -5.7% |
| 2011 | 0.42x | CN¥277.83 Million | CN¥665.51 Million | ▲ +148.6% |
| 2010 | 0.17x | CN¥115.66 Million | CN¥688.82 Million | ▼ -7.7% |
| 2009 | 0.18x | CN¥103.88 Million | CN¥571.26 Million | ▼ -40.4% |
| 2008 | 0.30x | CN¥189.26 Million | CN¥620.62 Million | ▲ +1458.1% |
| 2007 | 0.02x | CN¥11.94 Million | CN¥610.24 Million | ▼ -88.5% |
| 2006 | 0.17x | CN¥95.77 Million | CN¥562.27 Million | ▲ +539.5% |
| 2005 | 0.03x | CN¥17.38 Million | CN¥652.65 Million | ▲ +121.5% |
| 2004 | -0.12x | CN¥-44.80 Million | CN¥361.10 Million | ▼ -137.0% |
| 2003 | 0.34x | CN¥92.10 Million | CN¥274.93 Million | ▼ -20.3% |
| 2002 | 0.42x | CN¥73.46 Million | CN¥174.87 Million | — |